Scientists at the Institut Pasteur and their partners in the international TBVAC 2020 consortium have just developed a tuberculosis vaccine candidate derived from conventional BCG. This vaccine candidate has higher efficacy, due to a system of heterologous protein secretion that increases the quality and magnitude of the immune response to virulent strains of Mycobacterium tuberculosis - the bacterium responsible for the disease. These promising results were published in Cell Reports.

To find out more, read the press release